AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 216.52B +39.3% |
| Revenue (ttm) | 45.77B +9.9% |
| Net Income | 7.87B +33.7% |
| EPS | 5.03 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 27.76 |
| Forward PE | 17.66 |
| Dividend | 2.36 (1.69%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 3,227,532 |
| Open | 13,922 |
| Previous Close | 13,960 |
| Day's Range | 13,818 - 14,044 |
| 52-Week Range | 101 - 14,044 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 16,076.92 (+14.77%) |
| Earnings Date | Apr 29, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
AZN's Patent Granted in Canada Strengthens Position in Male Infertility Treatment
AZN's Patent Granted in Canada Strengthens Position in Male Infertility Treatment
AstraZeneca (AZN) Receives FDA Extension for Drug Review
AstraZeneca (AZN) Receives FDA Extension for Drug Review
AstraZeneca says FDA extends PDUFA date to review camizestrant data for NDA
The US Food and Drug Administration, FDA, has informed AstraZeneca (AZN) that it will extend the Prescription Drug User Fee Act, PDUFA, date to review additional data requested to support…
FDA Extends Review Of AstraZeneca's Camizestrant NDA In ESR1-Mutated Advanced Breast Cancer
(RTTNews) - AstraZeneca (AZN, AZN.L) announced that the US Food and Drug Administration or FDA will extend the PDUFA date to review additional data requested to support the New Drug Application or NDA...
AstraZeneca: FDA Extends PDUFA Date Related To NDA For Camizestrant
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the FDA has informed that it will extend the PDUFA date to review additional data requested to support the New Drug Application for camizestra...
US FDA extends review of AstraZeneca's experimental breast cancer pill
AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended its review deadline for its experimental breast cancer pill camizestrant to assess additional data.
Top losers in morning trade: gujarat state petronet at ₹268.35 down 7.13%, techno electric at ₹1,121.80 slips 6.61%, astrazeneca at ₹8,383.00 falls 6.47%
The Indian stock market showed mixed signals this morning with the SENSEX slightly up by 0.18% at 76,143.21 and the NIFTY 50 rising by 0.21% to 23,963.85. However, certain stocks…
How Big Pharma Is Turning Industrial Heat Into A Strategic Asset
Inside a pharmaceutical plant, heat is everywhere—and until recently, almost nobody was paying attention to it.
Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
The multiple myeloma market is evolving toward immunotherapy-dominated, multi-line treatment paradigms with strong growth driven by CAR-T and bispecific antibodies. Leading contenders advancing throug...
Insider Sell: Mani Sharma Sells Shares of AstraZeneca PLC
Insider Sell: Mani Sharma Sells Shares of AstraZeneca PLC
AstraZeneca (AZN) Engages With Key Opinion Leaders at ASCO 2023
AstraZeneca (AZN) Engages With Key Opinion Leaders at ASCO 2023
AstraZeneca to Present Key Clinical Findings at ASCO 2026
AstraZeneca to Present Key Clinical Findings at ASCO 2026
FDA Approves AstraZeneca And Daiichi's Datroway For Treating Metastatic Breast Cancer
(RTTNews) - AstraZeneca PLC (AZN), a biopharmaceutical company, and Daiichi Sankyo Company Limited (4568.T), a healthcare company, on Friday announced the approval of Datroway in the treatment of meta...
AstraZeneca (AZN) Gains U.S. Approval for Datroway in Breast Cancer Treatment
AstraZeneca (AZN) Gains U.S. Approval for Datroway in Breast Cancer Treatment
Daiichi Sankyo, AstraZeneca’s Datroway approved in U.S to treat TNBC
Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Datroway has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer who are not…
AstraZeneca (AZN) Showcases Promising Clinical Data at ASCO Annual Meeting
AstraZeneca (AZN) Showcases Promising Clinical Data at ASCO Annual Meeting
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with ...
AstraZeneca (AZN) Receives EU Approval Recommendation for Camizestrant
AstraZeneca (AZN) Receives EU Approval Recommendation for Camizestrant
AstraZeneca and Daiichi Sankyo’s Enhertu recommended in EU by CHMP in HER2
The company states: “AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union as a monotherapy for the treatment of adult...
AstraZeneca's Camizestrant Receives Positive Opinion from EMA
AstraZeneca's Camizestrant Receives Positive Opinion from EMA
AstraZeneca’s Camizestrant recommended for approval in EU by CHMP
The company states: “AstraZeneca’s (AZN) camizestrant in combination with a cyclin-dependent kinase 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been recommended for approval in the Euro...
AstraZeneca announces new data from portfolio, pipeline at ASCO meeting
AstraZeneca (AZN) announces new data across its portfolio and pipeline at the American Society of Clinical Oncology, ASCO, Annual Meeting, 29 May to 2 June 2026. EMERALD-3: Phase III trial…
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death and transform outcomes for people living with rare diseases with new data across its divers...
EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug
A European Medicines Agency committee said on Friday it has adopted a positive opinion of AstraZeneca's experimental breast cancer drug, camizestrant.
AstraZeneca designates key managerial personnel for materiality determination
AstraZeneca Pharma India has notified the National Stock Exchange of India and BSE Limited of the contact details of Key Managerial Personnel authorised to determine the materiality of events and…